SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalMunch-a-Biotech Today


Previous 10 Next 10 
From: tuck12/3/2018 9:32:32 AM
   of 3158
 
GSK takes out Tesaro (TSRO). I don't get it. They seem to me like something of an also ran in the PARP space. Whatever, sector could use the boost.

Cheers, Tuck

Share RecommendKeepReplyMark as Last Read


From: tuck1/3/2019 8:53:42 AM
1 Recommendation   of 3158
 
BMY takes out Celgene for 1 BMY share + $50 per share of CELG. About $102/share. Might juice the sector on what's shaping up to be bad Apple day.

Celgene Munch

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: tuck who wrote (3132)1/3/2019 2:42:03 PM
From: Miljenko Zuanic
   of 3158
 
So, generic "THALIDOMIDE" derivatives are worth $74B, after they "wasted" +85% of their sale potentials????

Very nice deal, BMY! Bravo! (MF in my book)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (3133)1/3/2019 6:48:06 PM
From: Biotech Jim
   of 3158
 
When the deal is consummated, I will look at the details of the contingent value rights. These CVRs could have several pipeline drivers. Also, assets to be shed due to "efficiencies" may be of interest to those in the bidness. Yessirreee, CELG CVRs.

FWIW, as I listen to REM and "Everybody Hurts", reflecting at least for me the carnage that I had the certainty that they would not go down this far. Hubris.

Everybody hurts, yes even me....

Share RecommendKeepReplyMark as Last ReadRead Replies (3)


To: Biotech Jim who wrote (3134)1/3/2019 7:23:11 PM
From: rkrw
1 Recommendation   of 3158
 
The CVR is based on final approval of all three drugs, with deadlines:

Ozanimod by 12/31/20
JCAR017 by 12/31/20
BB2121 by 3/31/21

The plus to them is it will be tradable. So maybe the CVR will sell for a few bucks once trading.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: rkrw who wrote (3135)1/3/2019 9:32:09 PM
From: Robohogs
   of 3158
 
All 3 must be approved as you mentioned. Interesting.

Share RecommendKeepReplyMark as Last Read


To: Biotech Jim who wrote (3134)1/3/2019 10:06:32 PM
From: scaram(o)uche
   of 3158
 
>> Hubris <<

Not the way I saw it. Just the usual, many years, helping people find good issues. Win some, lose some.

Great song for the moment, thanks for the link and thought.

Share RecommendKeepReplyMark as Last Read


To: Biotech Jim who wrote (3134)1/4/2019 3:13:23 AM
From: Miljenko Zuanic
   of 3158
 
H.Jim, thanks for the link.

As a BMY long SH (not very happy for last 18 months), I can only say that I am even less happy now with CELG deal. And, there is several reasons that I think that they overpaid for this deal. First BMY has several bad deals of late, and sugar over everything is CELG deal.

CELG IMIDs are slowly loosing strain, and IP will eat them inside out. Last 3 large deal, RCPT, Impact, and JUNO, (~$20B in total) are with questionable outcome. Ozanimod and Fedratinib are nothing more than me-too copy of current standard, while JUNO advantage over KITE is maybe nothing more than science-fiction. So, management that grounded CELG are now awarded with this lucrative deal. What message this send true bio-sector? We are ALL winners?????

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (3138)1/4/2019 2:06:00 PM
From: Miljenko Zuanic
2 Recommendations   of 3158
 
Who would ever guess....

fiercepharma.com

Share RecommendKeepReplyMark as Last Read


From: Robohogs1/7/2019 7:17:10 AM
   of 3158
 
Loxo $8 billion smackers, 68% premium, by Lily.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10